Pankaj Kumar | Cancer and Autoimmunity | Best Researcher Award

Dr. Pankaj Kumar | Cancer and Autoimmunity | Best Researcher Award 

Postdoc, at Ohio State University, Columbus, United States.

Dr. Pankaj Kumar is a Postdoctoral Research Scholar at the Ohio State University, specializing in molecular and cancer biology. With a passion for studying the DNA-damage response and multidrug resistance in cancer, his research explores the molecular mechanisms driving cancer metastasis, immunotherapy, and stem cell biology. Dr. Kumar holds a Ph.D. from the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, where he explored the role of Heat Shock Protein 90 (Hsp90) in drug-resistant cancer cells. His work spans the fields of cancer biology, hepatocellular carcinoma, and lupus nephritis. His notable contributions to cancer research and immunology have earned him multiple prestigious awards and grants. 🧬🌍

Profile

ORCID

Education

Dr. Pankaj Kumar’s academic journey reflects a solid foundation in molecular and cancer biology. He earned his Ph.D. (2014-2021) in Molecular and Cancer Biology from the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India, where his thesis focused on the role of Heat Shock Protein 90 (Hsp90) in drug-resistant cancer cells. Prior to this, Dr. Kumar completed his M.S. in Biotechnology (2011-2013) from Babasaheb Bhimrao Ambedkar University (BBAU), Lucknow, India. His undergraduate education began at Chhatrapati Shahu Ji Maharaj University (CSJMU), Kanpur, India, where he received his B.S. in Biotechnology (2008-2011). His robust academic background laid the foundation for his deep dive into cancer biology, drug resistance, and immunology. 🎓📚

Experience

Dr. Pankaj Kumar’s research experience spans across various prestigious institutions. Since February 2021, he has been a Postdoctoral Research Scholar at Ohio State University, Columbus, USA, focusing on cancer biology and immunotherapy. Before this, from August 2014 to October 2021, he was a Research Fellow (Ph.D. Scholar) at CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India, working under Dr. A. S. Sreedhar’s group. His expertise includes molecular pathways, tumor metastasis, and cancer immunotherapy. His research on drug resistance mechanisms has made significant contributions to cancer treatment advancements, making him a valuable asset to the field of molecular biology and cancer research. 🧪🔬

Research Interests

Dr. Kumar’s research spans multiple areas of cancer biology and immunotherapy, with a primary focus on the DNA-damage response, tumor metastasis, and multidrug resistance in cancer. His interests include the molecular basis of cancer progression, cancer immunotherapy, and stem cell biology. Additionally, he has explored the epithelial-to-mesenchymal transition (EMT), lupus nephritis, hepatocellular carcinoma, nonalcoholic fatty liver diseases (NAFLD), and non-alcoholic steatohepatitis (NASH). Dr. Kumar’s dedication to understanding cancer resistance mechanisms offers crucial insights into the development of new therapeutic approaches for treating aggressive and drug-resistant cancers. 🔬🧠

Awards

Dr. Pankaj Kumar has received several prestigious awards throughout his career. In 2019, he was awarded the Keystone Symposia Travel Award to attend the “Cancer Stem Cells” symposium in Hong Kong. He also received the Carl Storm International Diversity Fellowship from the Gordon Research Conference in 2018, which enabled him to attend the “GRC-Drug Resistance” event at Bryant University, USA. In addition, he was granted an International Travel Award from the Indian Council of Medical Research (ICMR) in 2018. His academic accolades include securing the CSIR-NET Junior/Senior Research Fellowship in 2015 and the DBT-JRF Junior Research Fellowship in 2014. 🏆🌟

Publications

Dr. Kumar has published extensively in renowned peer-reviewed journals. Some of his key publications include:

  • Kumar P, Devaki B, Jonnala UK, et al. Hsp90 facilitates acquired drug resistance of tumor cells through cholesterol modulation. Biochim Biophys Acta Mol Cell Res. 2020 Aug;1867(8):118728. DOI
  • Kumar P, Siripini S, Sreedhar AS. The matrix metalloproteinase 7 (MMP7) links Hsp90 chaperone with acquired drug resistance and tumor metastasis. Cancer Rep (Hoboken). 2020 Aug; DOI
  • Vykuntham NG, Kumar P, et al. Altered molecular pathways in breast cancer cells treated with Hsp90 inhibitors. Toxicol In Vitro. 2020 Jun; DOI
  • Hong Z, Kumar P, et al. Targeting squalene epoxidase enhances radiotherapy efficacy. Cancer Res. 2022 Apr; DOI
  • Kumar P, Schroder EA, Rajaram MVS, et al. The Battle of LPS Clearance in Host Defense. Cells. 2024; DOI

Conclusion

Dr. Pankaj Kumar is an outstanding candidate for the Research for Best Researcher Award due to his significant contributions to cancer biology and molecular mechanisms underlying drug resistance. His postdoctoral research, technical expertise, and numerous awards showcase his research excellence. With further diversification into immunology and greater international recognition, he would be an even more formidable candidate. Nevertheless, his current achievements alone make him highly deserving of consideration.

 

Sakthivel Muthu | Cancer biology | Best Researcher Award

Dr. Sakthivel Muthu | Cancer biology | Best Researcher Award 

Assistant Professor, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai-602105, Tamil Nadu, India.

Dr. Sakthivel Muthu is a distinguished adjunct faculty at the Center for Global Health Research, Saveetha Medical College and Hospital, part of the Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India. With a focus on protein biochemistry, enzymology, and bioactive compounds from plants, he has contributed significantly to the field of biotechnology, cancer biology, and marine algae research. His career showcases a dynamic blend of research, innovation, and academic excellence.

Profile

Scopus

Google Scholar

ORCiD

Education

Dr. Muthu completed his Ph.D. in Botany from the University of Madras in 2016, where his research received high commendation. He earned his M.Phil. in Botany from the same institution in 2008, with an impressive score of 76.39%. Prior to that, he completed his M.Sc. in Botany from Madurai Kamaraj University in 2007 and his B.Sc. in Botany in 2005. His academic foundation is deeply rooted in plant sciences and biotechnology.

Experience

Dr. Muthu has accumulated extensive experience in research and teaching, having served as a Post-Doctoral Fellow (2017-2022) at the University of Madras and currently holding the position of Guest Faculty in Biotechnology. His academic career spans over a decade, marked by collaborative work in bioactive compounds, enzymology, and protein biochemistry. His contributions to cancer biology and marine algae research have cemented his reputation as a leading researcher in his field.

Research Interests

Dr. Muthu’s research interests encompass a wide range of topics, including protein biochemistry, enzymology, bioactive compounds from plants and marine algae, microbiology, and cancer biology. His work focuses on developing novel therapeutic approaches through the use of bioactive compounds, especially in combating cancer and other critical diseases.

Awards and Fellowships

Over the course of his academic journey, Dr. Muthu has received several prestigious awards. Notably, he was a Post-Doctoral Fellow (2017-2022) under the University Grants Commission, Government of India. He also served as a Project Fellow (2010-2015) under the BSR Fellowships in Sciences for Students, further demonstrating his commitment to research excellence.

Publications

Dr. Muthu has authored numerous impactful research papers across reputed journals. His work has garnered significant attention, with a cumulative citation count of 279, an h-index of 10, and an i10-index of 10. Some of his notable publications include:

  • Encapsulation of Phloroglucinol from Rosenvingea intricata Macroalgae with Zinc Oxide Nanoparticles against A549 Lung Cancer Cells
    • Published in Pharmaceutics (2024).
    • Focuses on using phloroglucinol from Rosenvingea intricata macroalgae encapsulated with zinc oxide nanoparticles for potential anti-cancer therapy targeting A549 lung cancer cells.
    • Cited by 4.
  • Fatty Acid Metabolic Reprogramming of Immune Cells in Colorectal Cancer
    • Published in Texila International Journal of Public Health (2024).
    • Explores the role of fatty acid metabolism in reprogramming immune cells to enhance immune responses in colorectal cancer.
    • Cited by 5.
  • Anthocyanin-rich Foods: Insights into Extraction, Medicinal Potential, and Sustainable Applications
    • Published in Journal of Agriculture and Food Research (2024).
    • Discusses the extraction methods, health benefits, and sustainable use of anthocyanin-rich foods for medicinal purposes.
    • Cited by 7.
  • Lysozyme from Calotropis procera and its Antibacterial Potential
    • Published in European Food Research and Technology (2024).
    • Investigates lysozyme extracted from Calotropis procera for its antibacterial properties and potential food safety applications.
    • Cited by 10.
  • Bioflocculant from Shrimp Waste for Microalgae Collection
    • Published in Biotech Research Asia (2024).
    • Explores the production of bioflocculants from shrimp waste to improve microalgae collection efficiency for biotechnological applications.
    • Citation count not specified.

Conclusion

Dr. Sakthivel Muthu is a strong contender for the Best Researcher Award based on his wide-ranging research expertise, significant publication record, and noteworthy citation metrics. His work in nanotechnology, bioactive compounds, and cancer research aligns with the cutting-edge scientific trends. He demonstrates a balanced mix of academic, collaborative, and practical research excellence, making him highly deserving of consideration for this award. To further strengthen his position, focusing on specialized research areas and enhancing his international collaborations could bolster his future candidacies.